AR075882A1 - Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 - Google Patents
Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7Info
- Publication number
- AR075882A1 AR075882A1 ARP100100867A ARP100100867A AR075882A1 AR 075882 A1 AR075882 A1 AR 075882A1 AR P100100867 A ARP100100867 A AR P100100867A AR P100100867 A ARP100100867 A AR P100100867A AR 075882 A1 AR075882 A1 AR 075882A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr2
- cdr3
- seq
- chain cdr1
- cdr1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Ácido nucleico que lo codifica, un vector que lo comprende, una célula huésped, una composicion que comprende la proteína de union, método para matar una enfermedad seleccionada del grupo que consiste en pancreatitis, diabetes mellitus, asma entre otras. Reivindicacion 1: Una proteína de union al antígeno específica para el heterodímero alfa4beta7 aislada que tiene una region variable de cadena pesada que comprende CDR1, CDR2 y CDR3 y una region variable de cadena liviana que comprende CDR1, CDR2 y CDR3, en donde cada CDR respectiva se selecciona del grupo que consiste en: a) la CDR1, CDR2 y CDR3 de cadena liviana de la SEQ ID Ns:55, y la CDR1, CDR2 y CDR3 de cadena pesada de la SEQ ID Ns:58; b) la CDR1, CDR2 y CDR3 de cadena liviana de la SEQ ID Ns:56, y la CDR1, CDR2 y CDR3 de cadena pesada de la SEQ ID Ns:59; y c) la CDR1, CDR2 y CDR3 de cadena liviana de la SEQ ID Ns:57, y la CDR1, CDR2 y CDR3 de cadena pesada de la SEQ ID Ns:60.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16215409P | 2009-03-20 | 2009-03-20 | |
| US30682910P | 2010-02-22 | 2010-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075882A1 true AR075882A1 (es) | 2011-05-04 |
Family
ID=42224952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100867A AR075882A1 (es) | 2009-03-20 | 2010-03-18 | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US8444981B2 (es) |
| EP (1) | EP2408816B1 (es) |
| JP (3) | JP5498566B2 (es) |
| KR (2) | KR101391472B1 (es) |
| CN (2) | CN103382222B (es) |
| AR (1) | AR075882A1 (es) |
| AU (1) | AU2010226814B2 (es) |
| CA (2) | CA2754113C (es) |
| CL (3) | CL2011002306A1 (es) |
| CO (1) | CO6501170A2 (es) |
| CR (1) | CR20110544A (es) |
| EA (1) | EA034783B1 (es) |
| ES (1) | ES2751946T3 (es) |
| HK (1) | HK1168116A1 (es) |
| IL (4) | IL214868A (es) |
| JO (1) | JO3615B1 (es) |
| MA (1) | MA33213B1 (es) |
| MX (4) | MX338969B (es) |
| MY (2) | MY162752A (es) |
| NZ (1) | NZ595464A (es) |
| PE (2) | PE20120497A1 (es) |
| SG (3) | SG10201400798VA (es) |
| TN (1) | TN2011000433A1 (es) |
| TW (2) | TWI477511B (es) |
| UY (1) | UY32501A (es) |
| WO (1) | WO2010107752A2 (es) |
| ZA (1) | ZA201107279B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040855B2 (en) | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX366936B (es) * | 2011-11-23 | 2019-07-31 | Amgen Inc | Uso de un anticuerpo específico alfa4beta7. |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| CN106062193B (zh) * | 2014-02-28 | 2020-08-25 | 安斯泰来制药株式会社 | 与人tlr2及人tlr4结合的双特异性抗体 |
| MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
| CA2958673A1 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
| SG11201702793XA (en) | 2014-10-06 | 2017-05-30 | Chemocentryx Inc | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
| JP2017537105A (ja) | 2014-11-26 | 2017-12-14 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| EP3328994A4 (en) | 2015-07-31 | 2019-04-17 | Memorial Sloan-Kettering Cancer Center | CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF |
| MX2018001668A (es) | 2015-08-11 | 2018-05-07 | Univ Osaka | Anticuerpo. |
| IL261750B1 (en) * | 2016-03-14 | 2024-03-01 | Millennium Pharm Inc | A method for preventing graft-versus-host disease |
| WO2017160700A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| US10947299B2 (en) * | 2016-03-23 | 2021-03-16 | Seoul National University R&Db Foundation | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| US11389533B2 (en) | 2016-06-12 | 2022-07-19 | Takeda Pharmaceutical Company Limited | Method of treating inflammatory bowel disease |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| CA3061320A1 (en) | 2017-04-28 | 2018-11-01 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders |
| CN111954719A (zh) | 2018-03-26 | 2020-11-17 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| JP2022549329A (ja) | 2019-09-26 | 2022-11-24 | アムジェン インコーポレイテッド | 抗体組成物を製造する方法 |
| RS64645B1 (sr) | 2020-02-26 | 2023-10-31 | Vir Biotechnology Inc | Antitela protiv sars-cov-2 |
| EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| AU2022232943A1 (en) * | 2021-03-12 | 2023-09-28 | Icahn School Of Medicine At Mount Sinai | Neutralizing monoclonal antibodies to bk virus |
| CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen, Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US714785A (en) | 1901-07-03 | 1902-12-02 | Benjamin M Davis | Disinfecting apparatus. |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| NZ257942A (en) | 1992-10-23 | 1996-04-26 | Immunex Corp | Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US7435802B2 (en) * | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| AU703152B2 (en) | 1994-01-25 | 1999-03-18 | Biogen Ma Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| WO2001027279A1 (en) * | 1999-10-12 | 2001-04-19 | Cambridge Antibody Technology | Human anti-adipocyte monoclonal antibodies and their use |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| WO2002076406A2 (en) * | 2001-03-27 | 2002-10-03 | Gershwin M Eric | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them |
| WO2002078779A1 (fr) * | 2001-03-27 | 2002-10-10 | Zeon Corporation | Fil-guide medical |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| NZ542784A (en) | 2002-08-19 | 2008-07-31 | Astrazeneca Ab | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| DK2177537T3 (da) * | 2004-01-09 | 2011-12-12 | Pfizer | Antistoffer til MAdCAM |
| US7329737B2 (en) * | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
| JP2008535823A (ja) | 2005-03-25 | 2008-09-04 | キュラジェン コーポレイション | テネイシンの主要な抗原に対する抗体 |
| US7480268B2 (en) | 2005-07-28 | 2009-01-20 | Symbol Technologies, Inc. | System and method for multiprotocol wireless communication |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
-
2010
- 2010-03-16 WO PCT/US2010/027422 patent/WO2010107752A2/en active Application Filing
- 2010-03-16 MX MX2015002115A patent/MX338969B/es unknown
- 2010-03-16 TW TW103102822A patent/TWI477511B/zh active
- 2010-03-16 CA CA2754113A patent/CA2754113C/en active Active
- 2010-03-16 SG SG10201400798VA patent/SG10201400798VA/en unknown
- 2010-03-16 JP JP2012500875A patent/JP5498566B2/ja active Active
- 2010-03-16 PE PE2011001661A patent/PE20120497A1/es not_active Application Discontinuation
- 2010-03-16 MX MX2014013424A patent/MX357211B/es active IP Right Grant
- 2010-03-16 CN CN201310216898.1A patent/CN103382222B/zh active Active
- 2010-03-16 TW TW99107689A patent/TWI466681B/zh active
- 2010-03-16 MA MA34274A patent/MA33213B1/fr unknown
- 2010-03-16 NZ NZ595464A patent/NZ595464A/xx unknown
- 2010-03-16 KR KR1020137012483A patent/KR101391472B1/ko active IP Right Grant
- 2010-03-16 SG SG10201801337WA patent/SG10201801337WA/en unknown
- 2010-03-16 MY MYPI2011004308A patent/MY162752A/en unknown
- 2010-03-16 US US12/725,031 patent/US8444981B2/en active Active
- 2010-03-16 MY MYPI2015002744A patent/MY184957A/en unknown
- 2010-03-16 ES ES10708688T patent/ES2751946T3/es active Active
- 2010-03-16 MX MX2011009897A patent/MX2011009897A/es active IP Right Grant
- 2010-03-16 MX MX2016001889A patent/MX357213B/es unknown
- 2010-03-16 EP EP10708688.6A patent/EP2408816B1/en active Active
- 2010-03-16 PE PE2016000333A patent/PE20160553A1/es unknown
- 2010-03-16 SG SG2011065570A patent/SG174344A1/en unknown
- 2010-03-16 CN CN201080013557.9A patent/CN102388068B/zh active Active
- 2010-03-16 KR KR1020117024649A patent/KR101346530B1/ko active IP Right Grant
- 2010-03-16 AU AU2010226814A patent/AU2010226814B2/en active Active
- 2010-03-16 CA CA2851737A patent/CA2851737C/en active Active
- 2010-03-16 EA EA201171148A patent/EA034783B1/ru not_active IP Right Cessation
- 2010-03-18 JO JOP/2010/0090A patent/JO3615B1/ar active
- 2010-03-18 AR ARP100100867A patent/AR075882A1/es active IP Right Grant
- 2010-03-18 UY UY0001032501A patent/UY32501A/es not_active Application Discontinuation
-
2011
- 2011-08-24 TN TN2011000433A patent/TN2011000433A1/fr unknown
- 2011-08-29 IL IL214868A patent/IL214868A/en active IP Right Grant
- 2011-09-16 CL CL2011002306A patent/CL2011002306A1/es unknown
- 2011-09-30 CO CO11128767A patent/CO6501170A2/es not_active Application Discontinuation
- 2011-10-05 ZA ZA2011/07279A patent/ZA201107279B/en unknown
- 2011-10-18 CR CR20110544A patent/CR20110544A/es unknown
-
2012
- 2012-03-22 US US13/427,745 patent/US8454961B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,757 patent/US8454962B2/en not_active Expired - Fee Related
- 2012-09-12 HK HK12108929.5A patent/HK1168116A1/xx unknown
-
2013
- 2013-04-22 US US13/867,498 patent/US8871490B2/en active Active
-
2014
- 2014-02-18 CL CL2014000400A patent/CL2014000400A1/es unknown
- 2014-02-18 CL CL2014000401A patent/CL2014000401A1/es unknown
- 2014-03-06 JP JP2014043790A patent/JP5775615B2/ja active Active
- 2014-04-08 IL IL232009A patent/IL232009A/en active IP Right Grant
- 2014-04-08 IL IL232008A patent/IL232008A/en active IP Right Grant
- 2014-09-26 US US14/497,883 patent/US9499620B2/en active Active
-
2015
- 2015-07-03 JP JP2015134473A patent/JP5980384B2/ja active Active
- 2015-07-16 IL IL239965A patent/IL239965A/en active IP Right Grant
-
2016
- 2016-11-09 US US15/347,233 patent/US20170275365A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075882A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| AR072167A1 (es) | Anticuerpos contra il-6 humano y sus usos | |
| PE20120306A1 (es) | Anticuerpos anti-egfr y vectores que los codifican | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| RU2010133547A (ru) | Анти-cldn антитела | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| AR084315A1 (es) | Anticuerpos anti-notch1 | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| BRPI0821682A2 (pt) | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. | |
| AR075849A1 (es) | Moleculas de anticuerpos que tienen especificidad de union por il-13 humana | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| CL2010000470A1 (es) | Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo. | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |